



Dementia & Cognitive Impairment

Exclude delirium, depression and drugs first · what comes FIRST names the subtype · and the subtype decides what is safe to prescribe

Never diagnose
during acute illness

BEFORE THE LABEL *three exclusions, and the reversible cause is usually in the chart*

⚠ DELIRIUM

Acute onset, fluctuating, inattention. Cognitive testing during acute illness measures the delirium, not a baseline. **Labeling a delirious inpatient as demented stops the search for the cause and follows them in the chart forever.** Get collateral about pre-admission function, treat the illness, **re-test weeks after recovery** (delirium does predict cognitive vulnerability, so arrange the follow-up).

DEPRESSION

"Pseudodementia": **poor effort and "I don't know" answers** rather than confabulation, prominent low mood, subacute course. It is treatable, so it must be actively sought rather than assumed absent.

⚠ MEDICATIONS

Anticholinergics (oxybutynin, diphenhydramine, TCAs), benzodiazepines, opioids, sedative-hypnotics. Review the list *before* ordering the MRI: **the reversible contributor is more often in the medication list than on the scan.**

SUBTYPE: WHAT COMES FIRST *sequence discriminates better than the later picture, because all subtypes converge*

Type	Recognize it by	What changes
Alzheimer ~60-70%	Episodic memory first: repeating questions, recent events lost. Gradual over years, then language and visuospatial decline	Cholinesterase inhibitor ± memantine; anti-amyloid therapy only in early disease with confirmed amyloid
Vascular	Stepwise decline or clear link to strokes; early executive dysfunction and gait disturbance , focal signs, vascular burden on imaging	Vascular risk factor control IS the treatment: BP, lipids, diabetes, antiplatelet, smoking cessation. Preventing the next infarct is the therapy
⚠ Lewy body	Fluctuating cognition, well-formed visual hallucinations, spontaneous parkinsonism, REM sleep behavior disorder. Dementia within 1 year of motor symptoms (vs Parkinson disease dementia, motor first)	Severe neuroleptic sensitivity: antipsychotics can cause life-threatening rigidity and autonomic instability. Cholinesterase inhibitors work particularly well. Quetiapine, clozapine or pimavanserin only if unavoidable
Frontotemporal	Younger (45-65), personality, behavior or language change BEFORE memory: disinhibition, apathy, loss of empathy, hyperorality	Cholinesterase inhibitors do not help and may worsen behavior; memantine ineffective. SSRIs for behavior; genetic counseling
NPH	Gait apraxia FIRST ("magnetic"), then incontinence, then cognitive slowing. Ventriculomegaly out of proportion to atrophy	Potentially reversible with shunting; large-volume LP with gait testing before and after predicts response. Gait improves most, cognition least

WORKUP *targeted, not a shotgun*

Step	Detail
History and function	Collateral history beats any office test (finances, medications, driving, cooking), since impaired insight means patients under-report. MoCA is more sensitive than MMSE for MCI; a score is a data point, not a diagnosis , and a highly educated patient can decline substantially while still scoring "normal"
Labs and imaging	CBC, CMP, TSH, B12 in everyone; selective HIV and syphilis serology for young onset, risk factors or rapid course. Structural imaging once at diagnosis (MRI preferred) to exclude subdural hematoma, tumor, NPH and strokes. Amyloid PET and CSF are NOT routine: reserved for uncertainty, young or atypical presentations, and mandatory before anti-amyloid therapy
⚠ Red flags	Rapid progression over weeks to months (Creutzfeldt-Jakob, autoimmune encephalitis, malignancy) is a workup that cannot wait. Also onset before 65, early falls, early hallucinations, focal signs, or gait change preceding cognition

MANAGEMENT *the care plan outweighs the prescription*

DRUGS, HONESTLY FRAMED

Cholinesterase inhibitors and memantine **slow decline modestly; they do not restore function**, and families deserve that said rather than expecting recovery. Watch bradycardia and syncope. **Anti-amyloid therapy is narrow:** MCI or mild Alzheimer only, **amyloid confirmed by PET or CSF**, screening MRI (non-MRI-capable patients ineligible), and **APOE genotyping, since ε4 carriers and especially homozygotes have higher ARIA risk.** Surveillance MRIs are part of the therapy.

⚠ BEHAVIORAL SYMPTOMS

Agitation is usually communication. Look for pain (often the answer in a patient who cannot report it), infection, constipation, retention, fear or a new drug *before* prescribing; environmental and caregiver approaches beat antipsychotics on evidence. **Antipsychotics carry a boxed warning for increased mortality in dementia:** reserve for severe agitation or psychosis with risk of harm, lowest dose, documented risk discussion, **and a scheduled stop date.** Avoid benzodiazepines and anticholinergics.

Priority	Why it matters more than the prescription
Caregiver support	The highest-yield intervention: education, respite, support groups, and screening the caregiver for depression and burnout. Caregiver collapse usually precipitates institutionalization , not the patient's decline
Plan early, deprescribe broadly	Proxy, goals of care, feeding and hospitalization preferences while the patient can still participate: waiting until capacity is gone is the commonest failure in dementia care. Address driving, medication supervision, wandering and firearms, and deprescribe drugs whose benefit accrues over a longer horizon than the patient has (primary-prevention statins, tight glycemic targets, bisphosphonates)
⚠ Advanced disease	Feeding tubes do not help advanced dementia: no prevention of aspiration, no survival benefit, no pressure ulcer healing, while adding restraints and agitation. Careful hand feeding is the evidence-based alternative. Consider hospice with FAST stage 7, full ADL dependence or recurrent infections

PEARLS & PITFALLS

- **Memory first = Alzheimer.** Behavior first = frontotemporal. Hallucinations and fluctuation first = Lewy body. Gait first = NPH or vascular. Ask what changed first, not what is worst now.
- **Dementia is defined by lost independence, MCI by preserved independence:** ~10-15% of MCI progresses per year and some reverts, so it is monitored rather than treated as early dementia.
- **The visual hallucinations of Lewy body disease invite exactly the wrong drug.** The subtype is a safety decision, not an academic one.
- **Deprescribing often beats prescribing at the first visit:** oxybutynin and diphenhydramine can account for a surprising share of the deficit.

References: Alzheimer's Association appropriate use recommendations for amyloid-targeting therapy · AAN guidance on mild cognitive impairment · DSM-5 neurocognitive disorder criteria · consensus criteria for dementia with Lewy bodies and frontotemporal dementia.

Educational aid; verify against current guidance, local formulary and patient factors.

